PDCI Market Access recently launched the International Trends Series, which provides the results of an online survey PDCI conducted between March 19, 2015 and March 25, 2015. Participants were stakeholders in Europe and Canada. The first issue, “Delisting of Oncology Treatments” was released last week. This current issue reveals the perspective of off-label prescribing from industry and payers (public and private).
Please click here for a complimentary copy of the second issue, “Off-Label Prescribing Provisions.”
Over the coming weeks, we will be releasing a series of papers focusing on the following issues about which participants were asked to share their insights:
- Delisting of Oncology Treatments
- Off-Label Prescribing Regulations
- Downgrading of Benefits
- Uptake of Biosimilars
- Private Payer Exclusivity Agreements
If you have any questions regarding the paper, please contact Courtney Abunassar, PDCI’s Manager of Market Access and Policy Research.